SCHEMBL26554536

CC(=O)NC1[C@H](OC2[C@@H](OCC3O[C@@H](O[C@@H]4C(CO)O[C@@H](O)C(NC(C)=O)[C@H]4O)C(O)[C@@H](O[C@H]4O[C@@H](CO)[C@@H](O)C(O)C4O[C@@H]4OC(CO)[C@@H](O[C@@H]5OC(CO[C@]6(C(=O)O)C[C@@H](O)[C@@H](NC(C)=O)C([C@H](O)[C@H](O)CO)O6)[C@H](O)[C@H](O)C5O)[C@H](O)C4NC(C)=O)[C@@H]3O)OC(CO)[C@@H](O)[C@@H]2O)OC(CO)[C@@H](O[C@H]2C[C@@H](O)[C@@H](O)C(CO)O2)[C@@H]1O

nearest known ligand 0.61

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.61

▸	MAG	P20916	10/20	0.56

▸	SELL	P14151	1/20	0.51

▸	SELP	P16109	1/20	0.51

▸	SELE	P16581	2/20	0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30532209	0.96	SIGLEC7 (0.65)	SIGLEC7MAGSELLSELPSELE
SCHEMBL13004041	0.96	SIGLEC7 (0.65)	SIGLEC7MAGSELLSELPSELE
SCHEMBL26554465	0.93	SIGLEC7 (0.56)	SIGLEC7MAGSELLSELPSELE
SCHEMBL14570810	0.93	SIGLEC7 (0.62)	SIGLEC7MAGSELLSELPSELE
SCHEMBL30532210	0.92	SIGLEC7 (0.62)	SIGLEC7MAGSELLSELPSELE
SCHEMBL31701542	0.92	SIGLEC7 (0.68)	SIGLEC7MAGSELLSELPSELE
SCHEMBL31701064	0.92	SIGLEC7 (0.68)	SIGLEC7MAGSELLSELPSELE
SCHEMBL30970743	0.92	SIGLEC7 (0.68)	SIGLEC7MAGSELLSELPSELE
SCHEMBL31716709	0.92	SIGLEC7 (0.68)	SIGLEC7MAGSELLSELPSELE
SCHEMBL12534283	0.92	SIGLEC7 (0.63)	SIGLEC7MAGSELLSELPSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230330248-A1	ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE	DAIICHI SANKYO COMPANY, LIMITED (JP)	2023-10-19	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230330248-A1	ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE	STING1, CGAS, TLR9	SIGLEC7 141/4885MAG 1875/4885SELL 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.